

CLAIMS

1. A high-affinity monoclonal antibody, wherein the affinity is characterisable by:
  - (i) incubating first and second samples of the antibody in antigen-coated microtitre plate wells at a concentration chosen to be within the linear part of a standard curve at pH 7.2 for 1 hour at 37°C;
  - (ii) removing unbound antibody from both samples;
  - (iii) incubating the first sample with PBS at pH 7.2 for 1 hour at 37°C, and reducing the pH of the second sample to pH 3 or below and incubating for 1 hour at 37°C;
  - (iv) removing unbound antibody from both samples;
  - (v) incubating both samples with anti-antibody alkaline phosphatase-conjugate for 1 hour at 37°C;
  - (vi) removing unbound conjugate from both samples; and
  - (vii) adding PNPP substrate to the samples, measuring the absorbance of the samples at 405nm, and determining the amount of antibody bound to antigen, wherein the amount bound in the second sample is >50% of that of the first sample.
2. An antibody according to claim 1, wherein the amount of antibody bound in the second sample is >60% of that bound in the first sample.
3. An antibody according to claim 1 or claim 2, wherein the pH in step (iii) is reduced to pH 2.5 - pH 2.0.
4. An antibody according to any preceding claim, which is non-rodent.
5. An antibody according to any preceding claim, which has affinity for a tumour-associated antigen.
6. An antibody according to claim 5, wherein the antigen is carcinoembryonic antigen.
7. An antibody according to any preceding claim, which is a single-chain Fv, F(ab')<sub>2</sub>, Fv or fab.
8. An antibody according to claim 7, having a heavy chain variable region comprising the amino acid sequence defined in SEQ ID No. 2 and a light chain variable region

9. A polynucleotide molecule encoding an antibody  
5 according to claim 8, wherein the polynucleotide comprises  
a nucleotide sequence defined in SEQ ID Nos. 1 and 3, or a  
variant thereof.

AMENDED SHEET